Last reviewed · How we verify
LTLD
At a glance
| Generic name | LTLD |
|---|---|
| Also known as | ThermoDox, Lyso-Thermosensitive Liposomal Doxorubicin |
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors (PHASE2)
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (PHASE3)
- A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (PHASE1)
- Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients (PHASE2)
- Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer (PHASE1)
- Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LTLD CI brief — competitive landscape report
- LTLD updates RSS · CI watch RSS
- UMC Utrecht portfolio CI